tiprankstipranks
Encompass Health (EHC)
NYSE:EHC
US Market
Want to see EHC full AI Analyst Report?

Encompass Health (EHC) Stock Forecast & Price Target

461 Followers
See the Price Targets and Ratings of:

EHC Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Encompass
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EHC Stock 12 Month Forecast

Average Price Target

$147.43
▲(30.59% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is $147.43 with a high forecast of $155.00 and a low forecast of $140.00. The average price target represents a 30.59% change from the last price of $112.89.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"92":"$92","108":"$108","124":"$124","140":"$140","156":"$156"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$155.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147.42857142857142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$147.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$140.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[92,108,124,140,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.07,114.44923076923077,117.82846153846154,121.2076923076923,124.58692307692307,127.96615384615384,131.3453846153846,134.7246153846154,138.10384615384615,141.4830769230769,144.8623076923077,148.24153846153845,151.62076923076924,{"y":155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.07,113.86681318681318,116.66362637362637,119.46043956043955,122.25725274725274,125.05406593406593,127.85087912087911,130.6476923076923,133.44450549450548,136.24131868131866,139.03813186813187,141.83494505494505,144.63175824175823,{"y":147.42857142857142,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.07,113.2953846153846,115.52076923076922,117.74615384615385,119.97153846153846,122.19692307692307,124.42230769230768,126.6476923076923,128.87307692307692,131.09846153846155,133.32384615384615,135.54923076923077,137.77461538461537,{"y":140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107.758,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.894,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.819,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.209,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.054,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.543,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.469,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.645,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.196,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.277,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.536,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$155.00Average Price Target$147.43Lowest Price Target$140.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on EHC
Truist Financial
Truist Financial
$150
Buy
32.87%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Encompass Health (EHC)
Mizuho Securities Analyst forecast on EHC
Mizuho Securities
Mizuho Securities
$140
Buy
24.01%
Upside
Reiterated
08/11/26
Encompass Health (EHC) Receives a Buy from Mizuho Securities
TD Cowen
$125$140
Buy
24.01%
Upside
Assigned
08/10/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
UBS
$150$155
Buy
37.30%
Upside
Assigned
08/07/26
Encompass Health price target raised to $155 from $150 at UBSEncompass Health price target raised to $155 from $150 at UBS
Raymond James Analyst forecast on EHC
Raymond James
Raymond James
$130$150
Buy
32.87%
Upside
Reiterated
08/07/26
Encompass Health price target raised to $150 from $130 at Raymond JamesEncompass Health price target raised to $150 from $130 at Raymond James
Bank of America Securities Analyst forecast on EHC
Bank of America Securities
Bank of America Securities
$150$153
Buy
35.53%
Upside
Reiterated
08/06/26
Bank of America Securities Sticks to Its Buy Rating for Encompass Health (EHC)
Barclays
$140$144
Buy
27.56%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Encompass Health (EHC)
William Blair Analyst forecast on EHC
William Blair
William Blair
Buy
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
KeyBanc
Buy
Reiterated
06/12/26
Analysts' Top Healthcare Picks: Amgen (AMGN), Enliven Therapeutics (ELVN)
Stephens Analyst forecast on EHC
Unknown Analyst
Stephens
Not Ranked
Stephens
$140
Buy
24.01%
Upside
Reiterated
05/04/26
Stephens Reaffirms Their Buy Rating on Encompass Health (EHC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on EHC
Truist Financial
Truist Financial
$150
Buy
32.87%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Encompass Health (EHC)
Mizuho Securities Analyst forecast on EHC
Mizuho Securities
Mizuho Securities
$140
Buy
24.01%
Upside
Reiterated
08/11/26
Encompass Health (EHC) Receives a Buy from Mizuho Securities
TD Cowen
$125$140
Buy
24.01%
Upside
Assigned
08/10/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
UBS
$150$155
Buy
37.30%
Upside
Assigned
08/07/26
Encompass Health price target raised to $155 from $150 at UBSEncompass Health price target raised to $155 from $150 at UBS
Raymond James Analyst forecast on EHC
Raymond James
Raymond James
$130$150
Buy
32.87%
Upside
Reiterated
08/07/26
Encompass Health price target raised to $150 from $130 at Raymond JamesEncompass Health price target raised to $150 from $130 at Raymond James
Bank of America Securities Analyst forecast on EHC
Bank of America Securities
Bank of America Securities
$150$153
Buy
35.53%
Upside
Reiterated
08/06/26
Bank of America Securities Sticks to Its Buy Rating for Encompass Health (EHC)
Barclays
$140$144
Buy
27.56%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Encompass Health (EHC)
William Blair Analyst forecast on EHC
William Blair
William Blair
Buy
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)
KeyBanc
Buy
Reiterated
06/12/26
Analysts' Top Healthcare Picks: Amgen (AMGN), Enliven Therapeutics (ELVN)
Stephens Analyst forecast on EHC
Unknown Analyst
Stephens
Not Ranked
Stephens
$140
Buy
24.01%
Upside
Reiterated
05/04/26
Stephens Reaffirms Their Buy Rating on Encompass Health (EHC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
IMRXImmuneering
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Encompass Health

3 Months
Ann HynesMizuho Securities
Success Rate
18/27 ratings generated profit
67%
Average Return
+5.15%
Copying Ann Hynes's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +5.15% per trade.
1 Year
Ann HynesMizuho Securities
Success Rate
24/27 ratings generated profit
89%
Average Return
+20.21%
Copying Ann Hynes's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +20.21% per trade.
2 Years
Success Rate
10/10 ratings generated profit
100%
Average Return
+15.96%
Copying Matthew Gillmor CFA's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +15.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EHC Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
1
1
0
0
Buy
12
15
16
12
14
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
16
17
12
14
In the current month, EHC has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EHC average Analyst price target in the past 3 months is 147.43.
Each month's total comprises the sum of three months' worth of ratings.

EHC Financial Forecast

EHC Earnings Forecast

Next quarter’s earnings estimate for EHC is $1.36 with a range of $1.25 to $1.45. The previous quarter’s EPS was $1.55. EHC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EHC has Performed in-line its overall industry.
Next quarter’s earnings estimate for EHC is $1.36 with a range of $1.25 to $1.45. The previous quarter’s EPS was $1.55. EHC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EHC has Performed in-line its overall industry.

EHC Sales Forecast

Next quarter’s sales forecast for EHC is $1.60B with a range of $1.59B to $1.62B. The previous quarter’s sales results were $1.60B. EHC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EHC has Performed in-line its overall industry.
Next quarter’s sales forecast for EHC is $1.60B with a range of $1.59B to $1.62B. The previous quarter’s sales results were $1.60B. EHC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EHC has Performed in-line its overall industry.

EHC Stock Forecast FAQ

What is EHC’s average 12-month price target, according to analysts?
Based on analyst ratings, Encompass Health’s 12-month average price target is 147.43.
    What is EHC’s upside potential, based on the analysts’ average price target?
    Encompass Health has 30.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EHC a Buy, Sell or Hold?
          Encompass Health has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Encompass Health’s price target?
            The average price target for Encompass Health is 147.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $155.00 ,the lowest forecast is $140.00. The average price target represents 30.59% Increase from the current price of $112.89.
              What do analysts say about Encompass Health?
              Encompass Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of EHC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.